drugset / Trial / NCT07645924

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

NCT07645924

Phase 3 Recruiting 1800 enrolled Kallyope Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.

Timeline

Start
2026-07
Primary completion
2027-02
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Elismetrep Small molecule 10 mg Oral
Subject Elismetrep Small molecule 20 mg Oral

Indications